Response Genetics (RGDX) signs a provider contract with Blue Cross and Blue Shield of Illinois...


Response Genetics (RGDX) signs a provider contract with Blue Cross and Blue Shield of Illinois making it easier for physicians in the state to provide access to the company's diagnostic tests which help predict patients' response to cancer therapy. The health plan counts some 7.4M members. Shares +14.57% premarket. (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs